KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Cash: 2009-2024

Historic Change in Cash for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $187.7 million.

  • Biomarin Pharmaceutical's Change in Cash rose 112.23% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $574.7 million, marking a year-over-year increase of 622.58%. This contributed to the annual value of $187.7 million for FY2024, which is 513.53% up from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Change in Cash is $187.7 million, which was up 513.53% from $30.6 million recorded in FY2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Change in Cash peaked at $211.7 million during FY2020, and registered a low of -$61.9 million during FY2021.
  • Moreover, its 3-year median value for Change in Cash was $137.3 million (2022), whereas its average is $118.5 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Change in Cash plummeted by 129.23% in 2021, and later skyrocketed by 513.53% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Change in Cash (Yearly) stood at $211.7 million in 2020, then crashed by 129.23% to -$61.9 million in 2021, then soared by 321.80% to $137.3 million in 2022, then plummeted by 77.71% to $30.6 million in 2023, then soared by 513.53% to $187.7 million in 2024.